PCK 3.70% 2.8¢ painchek ltd

The technology doesn't offer enough of a difference to the...

  1. 26,623 Posts.
    lightbulb Created with Sketch. 1726
    The technology doesn't offer enough of a difference to the current process with the time saved only for 1 out of the 6 manual assessments. This limitation has always been the biggest issue for me, if only the facial assessment was required then the uptake will be a lot more easier to sell the technology especially globally as they don't need to know the APS manual process. There won't be any difference in what PCK is currently encountered while trying to commercialise globally right now even after FDA approval and then trying to commercialise into the US market, I would be very surprise if a US healthcare company don't see this limitation.
 
watchlist Created with Sketch. Add PCK (ASX) to my watchlist
(20min delay)
Last
2.8¢
Change
0.001(3.70%)
Mkt cap ! $45.80M
Open High Low Value Volume
2.8¢ 2.8¢ 2.8¢ $9.308K 332.4K

Buyers (Bids)

No. Vol. Price($)
3 473630 2.7¢
 

Sellers (Offers)

Price($) Vol. No.
2.8¢ 101572 5
View Market Depth
Last trade - 16.10pm 20/06/2024 (20 minute delay) ?
PCK (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.